#United States #San Diego #Arthrosi Therapeutics #Gout Treatment #pozdeutinurad

Arthrosi Therapeutics Achieves Enrollment Milestone in Gout Study

Arthrosi Therapeutics, Inc., a biotechnology firm headquartered in San Diego, is making noteworthy strides in its clinical development of Pozdeutinurad (previously known as AR882), a novel drug aimed at treating gout and tophaceous gout. Their pivotal Phase 3 clinical trial, dubbed REDUCE 1, has successfully reached over 50% patient enrollment. This advancement was announced on July 1, 2025, and is a significant achievement for the company, reflecting a growing interest among investigators and patients for innovative treatment options.

Trial Overview and Expectations

Pozdeutinurad is designed to act as a highly potent and selective URAT1 inhibitor, with the primary goal of reducing serum urate (sUA) levels, mitigating flare-ups, and resolving tophi in gout patients. The REDUCE 1 trial is pivotal in determining the efficacy and safety of this drug, and its rapid enrollment rate indicates strong enthusiasm for finding a transformative option for those suffering from this painful condition.

According to Dr. Robert T. Keenan, Chief Medical Officer at Arthrosi, the trial's progress mirrors the encouraging momentum seen in the REDUCE 2 study, which is already fully enrolled. With enrollment expected to be completed in the latter half of 2025, the company aims to conduct a thorough analysis and share data updates by Q2 2026.

In this randomized, double-blind, placebo-controlled study, about 750 gout patients will participate, including those diagnosed with tophi. Throughout the trial, patients will be assigned to one of three groups, where they will receive either 50 mg, 75 mg of Pozdeutinurad, or a placebo. The primary endpoint is the reduction of serum urate levels by the sixth month, with secondary endpoints focusing on the reduction of tophi and flare occurrences.

Understanding Gout and Its Challenges

Gout, a form of inflammatory arthritis, is prevalent in the United States, affecting approximately 13 million individuals, with about 2 million of those suffering from tophaceous gout. It occurs due to the crystallization of uric acid in joints and surrounding tissues, leading to debilitating pain and a decrease in overall quality of life. The kidneys play a crucial role in processing uric acid, and in more than 90% of gout patients, the failure to adequately excrete uric acid results in elevated levels that can trigger painful attacks.

Managing and monitoring serum urate levels is essential as part of an effective treatment and prevention strategy for gout. With the results from REDUCE 1, there is hope that Pozdeutinurad will play a vital role in helping patients regain their quality of life.

Future Outlook

The potential impact of Pozdeutinurad is significant, offering optimism to many who deal with the chronic pain associated with gout. As Arthrosi Therapeutics pushes forward, their commitment to success is evident, and the data garnered from REDUCE 1 could reshape how gout is treated in the future. As more information becomes available, the medical community and patients alike eagerly await the results, looking for a reliable solution to tackle this widespread condition.

For further details regarding the REDUCE 1 trial, individuals can visit the clinical trials registry at clinicaltrials.gov (identifier NCT06846515).

Company Background

Arthrosi Therapeutics, Inc. is at the forefront of developing effective treatments for gout. With a commitment to innovation and patient care, the company aims to provide solutions that address unmet needs in the healthcare market. With Pozdeutinurad moving through the clinical trial phases, Arthrosi's future looks promising as they strive to deliver transformative therapies for patients suffering from gout.